XML 73 R62.htm IDEA: XBRL DOCUMENT v3.7.0.1
Investments in Preferred Stock - Additional Information (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Mar. 10, 2017
Mar. 31, 2017
USD ($)
shares
Jun. 30, 2016
$ / shares
shares
Jun. 30, 2017
USD ($)
shares
Jun. 30, 2017
USD ($)
$ / shares
shares
Jun. 30, 2016
USD ($)
$ / shares
Dec. 31, 2016
USD ($)
Schedule of Investments [Line Items]              
Fair value of financial assets measured at fair value on a recurring basis       $ 269,759 $ 269,759   $ 335,307
Noncash dividend income on preferred shares         7,980 $ 0  
Purchases of preferred stock and warrants         1,161 $ 1,167  
Preferred stock              
Schedule of Investments [Line Items]              
Fair value of financial assets measured at fair value on a recurring basis       $ 144,742 $ 144,742   129,545
Fibrocell Science, Inc.              
Schedule of Investments [Line Items]              
Convertible preferred shares issued (in shares) | shares   1,161          
Number of common shares into which warrants are convertible (in shares) | shares   498,843          
Reverse stock split ratio 1-for-3            
Reverse stock split, conversion ratio 0.3333            
Convertible preferred shares, dividend rate         4.00%    
ZIOPHARM Oncology, Inc.              
Schedule of Investments [Line Items]              
Preferred shares, stated value (in usd per share) | $ / shares     $ 1,200     $ 1,200  
Threshold consecutive trading days, conversion of shares         20 days    
Preferred shares, dividend rate (in usd per share) | $ / shares         $ 12.00    
Preferred shares, dividend rate, for unconverted shares after conversion event (in usd per share) | $ / shares         24.00    
ZIOPHARM Oncology, Inc. | Minimum              
Schedule of Investments [Line Items]              
Preferred shares, conversion calculation, divisor (in usd per share) | $ / shares         $ 1.00    
Other Contractual Payments | Upfront and Milestone Payments | ZIOPHARM Oncology, Inc.              
Schedule of Investments [Line Items]              
Collaborative arrangement consideration received, number of preferred shares (in shares) | shares     100,000        
ZIOPHARM Oncology, Inc.              
Schedule of Investments [Line Items]              
Dividend income, number of preferred shares received (in shares) | shares       3,313 6,529    
Noncash dividend income on preferred shares       $ 4,042 $ 7,965    
ZIOPHARM Oncology, Inc. | Preferred stock              
Schedule of Investments [Line Items]              
Fair value of financial assets measured at fair value on a recurring basis       142,326 142,326   $ 129,545
Fibrocell Science, Inc.              
Schedule of Investments [Line Items]              
Purchases of preferred stock and warrants   $ 1,161          
Fibrocell Science, Inc. | Preferred stock              
Schedule of Investments [Line Items]              
Fair value of financial assets measured at fair value on a recurring basis       $ 2,416 $ 2,416